Michael P M, Levin M D, Garson O M
Cancer Genet Cytogenet. 1984 Aug;12(4):333-41. doi: 10.1016/0165-4608(84)90067-0.
A study of the chromosomes of 125 consecutive patients with acute lymphocytic leukemia (ALL) showed the same translocation between chromosomes #1 and #19 in 5 patients. In 4 of the 5, the t(1;19)(q21;q13) was present at diagnosis. The fifth patient, who had Philadelphia chromosome positive (Ph1+) ALL, developed t(1;19) in first relapse. Trisomy 1q was involved in 2 of the 5 patients; 3 patients had additional abnormalities. All patients had low white cell counts at presentation (less than 35 X 10(9)/L), and the 4 patients tested had common ALL antigen (CALLA) positive leukemic blast cells. All achieved complete remission, including the Ph1+ ALL patient in first relapse, and survival times ranged from 4 to 21+ mo from the time the t(1;19) first appeared. Our data suggest that t(1;19) is a previously unrecognized nonrandom structural abnormality in ALL that is also found in other lymphoid malignancies. Unlike the other specific translocations, it is not associated with a poor prognosis.
一项针对125例连续性急性淋巴细胞白血病（ALL）患者染色体的研究显示，5例患者的1号和19号染色体之间存在相同的易位。在这5例患者中的4例，诊断时即存在t(1;19)(q21;q13)。第5例患者为费城染色体阳性（Ph1+）ALL，在首次复发时出现t(1;19)。5例患者中有2例涉及1q三体；3例患者有其他异常。所有患者就诊时白细胞计数均较低（低于35×10⁹/L），4例接受检测的患者白血病原始细胞共同ALL抗原（CALLA）呈阳性。所有患者均实现完全缓解，包括首次复发时的Ph1+ ALL患者，从t(1;19)首次出现起，生存时间为4至21+个月。我们的数据表明，t(1;19)是ALL中一种先前未被认识的非随机结构异常，在其他淋巴恶性肿瘤中也有发现。与其他特定易位不同，它与预后不良无关。
